Comparing faricimab plus laser vs. surgery for diabetic eye disease
Treatments studied
Part of Eyes & vision clinical trials.
This study compares two approaches to treat advanced diabetic eye disease (proliferative diabetic retinopathy): injections of faricimab plus laser, versus surgery (vitrectomy) with laser. It is for people with diabetes who need treatment for PDR and still have relatively good vision (20/100 or better) in the affected eye.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have type 1 or type 2 diabetes.
- In the study eye, you have proliferative diabetic retinopathy (PDR) that needs treatment, confirmed by a special photo.
- Your best corrected vision in that eye is 20/100 or better (you can read the big E on an eye chart).
- You have not had certain eye surgeries or laser treatments in that eye (no prior vitrectomy, no prior extensive laser).
- You have not had treatment for diabetic macular edema in the last 6 months, or anti-VEGF injections (other than for DME) in the last year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments for early diabetic retinopathy—a condition where high blood sugar damages blood vessels in the eye. Researchers want to see if removing fluid from inside the eye (vitrectomy) works better than laser treatment to prevent vision loss.
This trial tests a different pattern of laser treatment for people with diabetic eye disease (proliferative diabetic retinopathy) that has started growing abnormal blood vessels. The goal is to see if this pattern works well or better than the standard approach.
This study compares two injectable medications (faricimab and biosimilar ranibizumab) used to treat diabetic retinopathy, a serious eye condition that can cause vision loss in people with diabetes. The trial will measure how well each medication works and track specific markers in your eye to understand treatment response.
This trial tests a new medicine, RRG001, given after vitrectomy surgery for severe diabetic eye disease. It aims to see if the drug is safe and helps prevent vision loss.
This study looks at how people with severe nonproliferative diabetic retinopathy do after they have vitrectomy (a type of eye surgery). The goal is to better predict prognosis and possibly improve care planning after surgery.
This trial tests a new eye injection called faricimab to treat diabetic macular edema (swelling in the back of the eye) in South Asian patients. The goal is to see how well it works, how long the effects last, and if it is safe.
Hear when a new Proliferative Diabetic Retinopathy (PDR) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.